Recent News

• 12.12.2025 - Teva Releases Q4 2025 Aide Memoire
• 12.12.2025 - Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
• 12.09.2025 - Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
• 11.25.2025 - Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
• 11.21.2025 - Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
• 11.19.2025 - Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

Recent Filings

• 12.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2025 - 8-K Current report
• 12.09.2025 - 144 Report of proposed sale of securities
• 12.09.2025 - 144 Report of proposed sale of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.26.2025 - 144 Report of proposed sale of securities
• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.20.2025 - 144 Report of proposed sale of securities